10.460

-17.030 (-61.95%)
Range 9.550 - 12.150   (27.23%)
Open 12.020
Previous Close 27.490
Buy Price 10.870
Buy Volume 14
Sell Price 10.910
Sell Volume 13
Volume 41,433,872
Value -
Remark
Measurement Type Value
EPS (USD) -0.794
Trailing EPS (USD) -0.909
NAV (USD) 5.176
Cash In Hand (USD) 0.983
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 2.021
Price / Cash In Hand 10.643
Issued & Paid-up Shares 69,749,600
Treasury Shares -
Market Cap (M) 729.581
Par Value (USD) n.a.
Beta - 75 Days 1.309
R-Squared - 75 Days(%) 4.1
Beta - 500 Days 1.126
R-Squared - 500 Days(%) 2.03
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 08 May 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 10 May 2021
View All Events

About CHEMOCENTRYX INC

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�s wholly owned subsidiary is ChemoCentryx Limited.

Loading Chart...